Paper Details

  1. Home
  2. Paper Details

Bortezomib for the treatment of multiple myeloma.

Author: CoyneImelda, HaydenPatrick J, ScottKathleen, WheatleyKeith, WillAndrea

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Meta-AnalysisA statistical technique that integrates the results of multiple studies to draw more general conclusions about a particular issue.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.
ReviewAn article that critically examines existing research on a particular topic and summarizes the current state of knowledge in the field.
Systematic ReviewA review that systematically collects, evaluates, and integrates relevant research to answer a specific research question.

Overview

Bortezomib, a drug that blocks the action of proteasomes (cellular machines that break down proteins), is a common treatment for multiple myeloma, a type of blood cancer. It is used both for newly diagnosed patients and for those whose disease has returned or stopped responding to other therapies. Bortezomib is often given as a single drug or combined with other treatments.
Paper Details　
Original Abstract of the Article :
Multiple myeloma is a malignancy of plasma cells accounting for approximately 1% of cancers and 12% of haematological malignancies. The first-in-class proteasome inhibitor, bortezomib, is commonly used to treat newly diagnosed as well as relapsed/refractory myeloma, either as single agent or combine...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10387344/

データ提供：米国国立医学図書館（NLM）

Bortezomib: A Powerful Weapon Against Multiple Myeloma

Multiple myeloma, like a relentless desert storm, wreaks havoc on the body, affecting the bone marrow and immune system. This study, like a determined explorer seeking a cure, investigates the use of bortezomib, a potent medication, in the treatment of this challenging disease. The researchers delve into the effectiveness of bortezomib, a proteasome inhibitor, in treating both newly diagnosed and relapsed/refractory myeloma, offering hope for patients battling this formidable foe. The study provides a comprehensive overview of bortezomib's role in treatment regimens, highlighting its ability to control the disease and improve outcomes for patients.

Fighting a Destructive Storm with Precision

Bortezomib, like a well-aimed arrow, targets the proteasome, a vital component of the cell's protein degradation pathway. The study reveals the significant benefits of bortezomib in controlling the disease, particularly when combined with other therapies. The research, like a meticulous desert map, outlines the complex landscape of multiple myeloma treatment, providing valuable information for healthcare professionals and patients alike.

Living with Multiple Myeloma: A Guide to Hope

Remember, like a desert traveler enduring the harsh elements, individuals with multiple myeloma face a challenging journey. It's crucial to work closely with your healthcare provider to develop a treatment plan that best suits your individual needs. Bortezomib, like a refreshing oasis, offers hope and a chance to fight back against this relentless disease. Stay informed, embrace your treatment plan, and seek support from trusted sources. Your journey, like the desert itself, can be transformative, filled with resilience and the unwavering pursuit of a better tomorrow.

Dr. Camel's Conclusion

This study provides valuable insights into the use of bortezomib in the treatment of multiple myeloma, offering hope for patients battling this challenging disease. Like a brave explorer navigating the vast desert, researchers continue to seek innovative solutions to improve patient outcomes and empower them to live fulfilling lives.

Date :
  1. Date Completed 2016-07-21
  2. Date Revised 2023-08-01
Further Info :

Pubmed ID

27096326

DOI: Digital Object Identifier

PMC10387344

Related Literature

Article Analysis
・Effective treatment of multiple myeloma
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.